Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Uroplakin II antibody IVD, 7/13:104

Biocare Medical’s uroplakin II mouse monoclonal antibody (IVD) is now available. Studies have shown UP II mRNA to be expressed in bladder cancer tissues and the peripheral blood of patients with primary and metastatic urothelial carcinoma. Pathologists have used uroplakin III [AU1] to establish urothelial origin of the bladder; however, use of UP III is limited owing to its poor sensitivity. UP II was found to have 79 percent (44/56) sensitivity for bladder urothelial carcinoma compared with 34 percent (19/56)

MRSA/SA test, 7/13:104

Cepheid has received FDA clearance to market its Xpert MRSA/SA blood culture test, which runs on its GeneXpert system, for the detection of methicillin-resistant Staphylococcus aureus and S. aureus in blood culture bottles showing gram-positive cocci in clusters in about one hour. Cepheid’s updated Xpert MRSA/SA BC test processes positive blood culture specimens to determine whether a patient’s blood is infected with MRSA or SA, which are frequent causes of sepsis in hospitalized patients. “Having the capability to differentiate MRSA, S.

CAP 15189 renewal for National Jewish Health, 7/13:104

The College of American Pathologists has renewed CAP 15189 Accreditation for National Jewish Health Advanced Diagnostic Laboratories. The accreditation, based on standard 15189 for laboratory technical competence and continual quality management, is administered by the International Organization for Standardization and seeks to improve patient safety and reduce risk, by outlining standards for quality and competence in medical laboratories. CAP 15189 is a voluntary, non-regulatory accreditation to the ISO 15189:2007 standard as published by ISO. The program complements CAP accreditation and

Remote microscopy telepathology tool, 7/13:104

MikroScan Technologies’ Live-Q telepathology tool works as an add-on to the company’s D2 desktop whole slide scanner, which enhances remote viewing and remote control of the device. Keith J. Kaplan, MD, surgical pathologist and producer of the Digital Pathology Blog, recently tested the Live-Q user experience in a café over a standard typical Wi-Fi connection. He wrote in his review, “In summary, this system works on every level. It’s fast, it’s responsive, it’s intuitive, it’s high quality, and it’s easy

Troponin I assay, 7/13:104

Beckman Coulter has received FDA 510(k) clearance for its Access AccuTnI+3 troponin I assay for use on its Access 2 immunoassay system. In accordance with FDA requirements, the company conducted a large multicenter prospective clinical trial on the AccuTnI+3 troponin I assay that enrolled more than 1,900 subjects, and confirmed that the assay provides the clinical performance necessary for optimal patient management. The data from this trial show that Beckman Coulter’s Access AccuTnI+3 troponin I assay provides the precision, clinical

Rabbit monoclonal antibodies portfolio, 7/13:104

Bio SB offers a portfolio of more than 130 rabbit monoclonal antibodies. “Rabbit monoclonal antibodies offer higher sensitivity and specificity when compared to mouse monoclonal antibodies traditionally used in laboratory applications,” Alfonso Heras, president and CEO of Bio SB, said in a statement. “Coupled with our new line of detection systems and chromogens, such as our PolyDetector HRP Plus, PolyDetector AP, and HRP Green, Bio SB can offer a large array of immunohistochemistry products to pathologists around the world.”

Hematology analyzer, 6/13:96

Beckman Coulter’s UniCel DxH 600 Coulter cellular analysis system is a benchtop hematology analyzer for mid- to high-volume laboratories. The system provides laboratories with exceptional quality results, improved first-pass accuracy, and automatic rerun and reflex testing, thereby reducing overall manual review rates and processes.

Next-generation lab automation solution

Abbott has launched its Accelerator a3600 next-generation automation solution, which helps laboratories process tests faster while handling increased volume. The Accelerator a3600 processes up to 3,600 samples per hour and handles multiple tube sizes and types simultaneously.

Multiplexing system with GI pathogen panel, 6/13:96

Luminex has received FDA clearance for its Magpix instrument with the xTAG gastrointestinal pathogen panel (xTAG GPP). This is the first clinical assay to be cleared on Magpix. xTAG GPP simultaneously detects 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single patient sample.

MARKETPLACE

TRENDING